Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study
Interview: At ESMO 2025, Professor Igle Jan de Jong shared new insights from the REASSURE study, highlighting that the combination of enzalutamide and radium-223 is safe, well-tolerated, and promising for patients with mCRPC.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
